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We studied the prevalence of hepatitis C virus infection among blood donors from 3 hospitals of 
Central Myanmar and 7 hospitals of Lower Myanmar in the Yangon area,  and analyzed the factors 
associated with the infection.  The study period was from November,  2005 to June,  2007.  A pre-tested 
questionnaire was used to obtain information on age,  ethnic group,  marital status,  tattooing,  body 
piercing,  history of receiving transfusions,  and liver diseases in self and in sexual partners.  Data on 
seropositivity to hepatitis C,  hepatitis B and human immunodeﬁciency virus infections were recorded.  
A total of 65,240 blood donors participated in the study.  Their ages ranged from 18 years to 60 years 
(mean±SD＝29.5±9.3).  The male-to-female ratio was 6：1.  The prevalence of the antibody to hepa-
titis C was found to be 0.95ｵ with varying rates (0.34 to 2.03) among hospitals.  Females had a slightly 
higher rate (1.06ｵ) than males (0.93ｵ) (p＝0.237).  Multivariate analyses revealed the following factors 
to be related to HCV infection: HIV infection,  odds ratio (OR)＝3.0 (p＝0.003); history of liver disease,  
OR＝8.9 (p＝0.001); and age 30 years and above,  OR＝2.6 (p＝0.001).  We discuss the varying preva-
lences of HCV around the world.
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epatitis C virus (HCV) infection is an important 
health problem in many countries [1].  
According to a review in 2000,  3 percent of the 
worldʼs population or almost 200 million persons are 
infected with HCV [2].  HCV has been shown to be 
associated with blood transfusion; although the acute 
infection is usually asymptomatic,  the subsequent 
chronic infection is usually life-long and may lead to 
chronic liver disease,  liver cirrhosis,  and hepatocel-
lular carcinoma.  In fact in Japan where the incidence 
of hepatitis B virus infection is low,  HCV has been 
proven as the single most important etiological factor 
for the development of hepatocellular carcinoma,  [3].
　 HCV is regarded as an emerging health problem in 
Myanmar.  Reports in the early 90s showed HCV 
infection in one-third of patients with hepatocellular 
carcinoma (Khin-Pyone-Kyi et al.,  (1992) presented at 
the 38th Myanmar Medical Conference,  Yangon),  and 
in 2.5ｵ of apparently healthy subjects (Khin-Pyone-
Kyi et al.,  (1995) presented at the Myanmar Health 
Research Congress,  Yangon) in Myanmar.
　 In May,  2000,  anti-HCV testing was introduced at 
blood banks in Yangon.  From May,  2000 to October,  
2003,  a total of 102,632 donors were screened,  and 
the overall anti-HCV positivity rate was found to be 
2.8ｵ (Paing-Soe et al.,  (2002) presented at the 
H
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Myanmar Health Research Congress,  Yangon).  In 
2005,  hepatitis C screening of blood donors was 
extended to Upper Myanmar.  Blood banks from major 
hospitals in Mandalay and Magwe were included in the 
protocol.  Although more data on the prevalence of 
HCV infection among blood donors became available 
(Myo-Khin et al.,  (2006) presented at the Myanmar 
Health Research Congress,  Yangon),  blood bank 
personnel have emphasized a lack of information on the 
factors associated with HCV infection in blood 
donors.  
　 We carried out this study to determine the associ-
ated factors of HCV infection in blood donors for use 
in the deferral of high-risk blood donors.  
Subjects and Methods
　 Blood donors from 3 hospitals in Central Myanmar 
(Mandalay General Hospital,  Magwe General Hospital,  
Pyinmana Township Hospital) and 7 hospitals (Yangon 
Children Hospital,  Central Women Hospital,  East 
Yangon General Hospital,  West Yangon General 
Hospital,  Insein General Hospital,  Thingangyun 
Sanpya Hospital and North Okkalapa General 
Hospital) in the Yangon area were included.  Prior to 
the study,  informed consent was obtained from each 
donor.  The study was conducted in accordance with 
the principles of Good Clinical Practice and the 
Declaration of Helsinki.  
　 The OneStep HCV RapiDip test (CORTEZ 
Diagnostics Inc.  Calabasas,  CA,  USA) was used at 
the hospitals for HCV seropositivity screening.  This 
one-step test is based on the principle of a double 
antigen sandwich immunoassay for determination of 
anti-HCV in serum.  It is very sensitive and only takes 
10-20 min for the result to be read.  Test results are 
read visually without any instrument.
　 The study period was from November,  2005 to 
June,  2007.  A pre-tested questionnaire was used to 
obtain information on age,  ethnic group,  marital sta-
tus,  tattooing,  body piercing,  history of receiving 
transfusions,  and liver diseases in self and in spouses.  
Data was collected by the laboratory personal from the 
participating hospitals.  Data on seropositivity to 
hepatitis C,  hepatitis B and human immunodeﬁciency 
virus infections were also recorded.  
　 Statistical methods. Data analysis was per-
formed with computer software MINITAB Statistical 
Package Version 14.1; MINITAB Inc.,  (PA,  USA) 
The chi-square test or Fisherʼs exact test was used as 
appropriate to evaluate the statistical signiﬁcance in 
the distribution of each factor between blood donors 
who were seropositive and seronegative hepatitis C.  
Multiple logistic regression analysis was used to 
determine the independent association between poten-
tial factors and HCV seropositivity after controlling 
for potential confounding factors.  Crude and adjusted 
odd ratios (ORs) and 95 percent conﬁdence intervals 
(CIs) were calculated [4].  
Results
　 General characteristics. A total of 65,240 
blood donors participated in the study.  Their ages 
ranged from 18 years to 60 years (mean±SD＝29.5
±9.3).  Male blood donors dominated female blood 
donors with a ratio of 6：1.  Females were signiﬁ-
cantly older than the males (Table 1).
　 HCV antibody prevalence. The prevalence of 
the antibody to hepatitis C among the study population 
was found to be 0.95ｵ.  The HCV seropositivity rate 
in blood donors varied from 0.34 to 2.03 among hospi-
tals (Table 2).
　 Females had a slightly higher prevalence of anti-
HCV seropositivity than males (1.06ｵ vs 0.93ｵ;  
Studentʼs t test,  p＝NS).  The anti-HCV seropositiv-
ity rate increased with increasing age group with the 
exception of the oldest group.  It was found to be the 
lowest (0.53ｵ) in the 18-20 years age group and 
highest (1.88ｵ) in the 41-50 years age group (Table 
3).
　 Associated risk factors for anti-HCV sero-
positivity. After univariate analysis,  it was found 
that the signiﬁcant associated factors among the popu-
lation were: (a) marital status,  (b) history of liver 
disease,  (c) age of 30 years and above,  (d) hepatitis B 
surface antigen seropositivity,  and (e) presence of the 
antibody to HIV.  There was no signiﬁcant association 
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Table 1　 Mean age of blood donors in relation to gender
Sex Number Mean age (yrs)±SD Studentʼs ʻtʼ test
Males 55920 29.4＋9.3 T-value 7.25
Females 9320 30.2＋9.2 df＝11981
Both 65240 29.5＋9.3 P-value＝0.0001
with sex,  history of receiving transfusions,  history of 
body piercing,  history of tattooing,  or history of 
hepatitis in spouse.  (Table 4).
　 Multiple logistic regression was applied for con-
trolling confounders and for evaluating the eﬀects of 
associated factors on HCV infection in the blood 
donors.  After analysis,  3 variables history of liver 
disease,  age of 30 years and above,  and presence of 
the antibody to HIV were found to have an eﬀect on 
the presence of HCV infection.  (Table 5).
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Table 2　 HCV seropositivity rate in blood donors by participating 
hospitals









Children Hospital Yangon 6,716 58 0.86
Central Women HospitalH 6,022 44 0.73
East Yangon General Hospital 1,847 16 0.87
West Yangon General Hospital 919 12 1.31
North Okkalapa General Hospital 8,397 45 0.54
Insein General Hospital 2,274 9 0.40
Sanpya General Hospital 4,630 23 0.50
Mandalay General Hospital 31,079 351 1.13
Magwe General Hospital 3,060 62 2.03
Pyinmana Hospital 293 1 0.34
Table 3　 Anti-HCV seropositivity by age group
Age group Total Anti-HCV seropositivity
Positive (％) Negative (％)
18-20 yrs 10907 58 (0.5％) 10,849 (99.3％)
21-30 yrs 27596 186 (0.7％) 27,410 (99.3％)
31-40 yrs 14923 211 (1.4％) 14,712 (98.6％)
41-50 yrs 7489 141 (1.9％) 7,348 (98.1％)
51-60 yrs 1608 23 (1.4％) 1,585 (98.6％)
Chi-Square＝142.907, DF＝4, P-Value＝0.0001
Table 4　 Associated factors for anti-HCV seropositivity by univariate analysis
Anti-HCV seropositivity
Associated factors No.  tested No.  positive (％) p value
Sex Male 56,383 526 (0.93) p＝0.237
Female 8,834  94 (14.2)
Marital status Never 14,942 183 (1.22) p＝0.001
Ever 48,628 426 (0.88)
History of liver diseases Yes 47   3 (6.38) p＝0.01
No 65,189 618 (0.95)
History of receiving transfusion Yes 59   0 (0.00) p＝0.907
No 65,177 621 (0.95)
History of body piercing Yes 638   2 (0.31) p＝0.095
No 64,598 619 (0.96)
History of tattooing Yes 408   4 (0.98) p＝0.953
No 64,828 617 (0.95)
History of hepatitis in spouse Yes 5   0 (0.00) p＝0.90
No 65,230 620 (0.95)
Age 30 years and above Yes 23,645 375 (1.56) p＝0.001
No 38,502 244 (0.63)
Hepatitis B surface antigen seropositivity Positive 2,221  11 (0.50) p＝0.024
Negative 63,015 610 (0.97)
Antibody to HIV Positive 288   8 (2.78) p＝0.001
Negative 64,948 613 (0.94)
Discussion
　 The problem of hepatitis C virus infection in 
Myanmar is well recognized,  and eﬀorts to control it 
in the blood donor population were initiated in 2000.  
Hepatitis C screening of 154,161 blood donors from 
May,  2000 to April,  2004 demonstrated the preva-
lence of HCV infection among Myanmar blood donors 
to be 2.6ｵ [5].  Low HCV seropositivity in blood 
donors (＜1ｵ) has been reported from Europe [2] 
and the Far East (1ｵ) [6].  However,  high rates of 
HCV infection had been reported in Egypt,  with 4ｵ 
of blood donors being positive for anti-HCV antibodies 
and a higher prevalence rate of 15ｵ in the rural areas 
of the country [7].  The HCV prevalence in Myanmar 
could be termed intermediate as the global seropreva-
lence of HCV among blood donors varies from 0.4 to 
19.2ｵ [8].
　 The present study highlights the increasing preva-
lence of anti-HCV seropositivity with age.  The lowest 
seropositivity was observed in the 18-20 years age 
group; and seropositivity tended to increase with age 
reaching a maximum in the 41-50 years age group.  
Comparable results have been observed in studies on 
blood donors from India [9].  A similar pattern has 
also been reported from Japan [10],  most likely due 
to the tumultuous period after World War II,  marked 
by illicit intravenous amphetamine abuse and unsafe 
healthcare-related procedures like the use of unsafe 
needles in group vaccinations.  With these results in 
mind,  eﬀorts should be made to increase retain young 
motivated voluntary donors to maintain a safe blood 
supply.  
　 The seroprevalence of HCV in voluntary blood 
donors from diﬀerent hospitals in India was shown to 
vary between 0.12 and 4 percent [11].  In the present 
study,  HCV seropositivity among blood donors varied 
from hospital to hospital.  Although the diﬀerences 
could be geographical in nature,  a recent study high-
lights the beneﬁt of earlier introduction of hepatitis C 
screening,  as evidenced by the lower rates of hepatitis 
C seropositivity among blood donors in Yangon com-
pared to Mandalay and Magwe (Myo-Khin et al.,  
(2006) presented at the Myanmar Health Research 
Congress,  Yangon).  This ﬁnding is also supported by 
the results of the present study where anti-HCV 
seroprevalence among blood donors in hospitals from 
Yangon was much lower than that of blood donors 
from Mandalay and Magwe.  
　 The present study highlights the associated factors 
of HCV infection among blood donors.  A previous 
history of liver diseases,  age of 30 years and older,  
and seropositivity to HIV were identiﬁed as indepen-
dently associated factors.  Coinfection with HIV and 
the hepatitis C virus (HCV) has been reported in the 
past.  The diseases are spread in similar ways,  nota-
bly through shared use of needles to inject illicit drugs 
and sexual activities.  Many people are coinfected with 
HIV and HCV,  HIV and HBV,  or even all 3 viruses 
[12].  A previous study carried out among Yangon 
blood donors also outlined associated factors.  A 
higher prevalence of anti-HCV positivity was found in 
those with a history of surgical operation,  tooth 
extraction,  ear piercing and tattooing (Thein-Saw et 
al.,  (1998) presented at the Myanmar Health Research 
Congress,  Yangon).  However,  due to the nature of the 
present study,  only minimal relevant data could be 
collected.
　 Variables that could cause confusion and were dif-
ﬁcult to recall were not included.  It was decided that 
an individualʼs history of surgical operation and tooth 
extraction procedures might not be easily deﬁned and 
thus were excluded from the data collection form.  Ear 
piercing was also not included as it is a very common 
practice among the Myanmar population,  especially 
among females.  
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Table 5　 Factors associated with anti-HCV seropositivity among blood donors by multivariate analysis
Associated factors Adjusted OR 95％ CI of OR p value
History of liver diseases Yes 8.86 2.65-29.65 p＝0.001
No 1
Age 30 years and above Yes 2.59 2.18- 3.08 p＝0.001
No 1
Presence of antibody to HIV Yes 2.96 1.46- 6.02 p＝0.003
No 1
　 Although HCV prevalence surveys among blood 
donors could not be considered to be representative of 
the population at large,  it could be concluded that the 
prevalence of HCV infection in blood donors is gener-
ally less than that in the general population as demon-
strated by surveys carried out among apparently 
healthy populations.  The prevalence of the antibody to 
HCV was found to be 2.8ｵ among 569 subjects (246 
males,  323 females),  aged 3 months to 74 years 
residing in Yangon [13].  It has been reported that 
rates of HCV infection among populations residing in 
border areas of Myanmar were higher (＞10ｵ) than 
that of blood donors from Yangon and Mandalay [14].  
　 The risk factors for HCV seropositivity among 
Israelis include gum surgery,  hospitalization without 
surgery,  and therapy in injection form [15].  We did 
not include these items in our data form as our previ-
ous studies among blood donors and the general popu-
lation did not establish them as signiﬁcant factors in 
Myanmar [13,  14].  A study from Australia identiﬁes 
the use of injected drugs as a potential risk factor 
[16].  However,  drug use is not easy to deﬁne,  and as 
self-revelation of such a factor is also not dependable,  
it was not included in the data collection form.
　 The present study was based on the experiences of 
a ﬁeld study where characteristics of hepatitis C 
seropositive subjects from communities in the border 
areas of Myanmar were used to develop a simple cost-
free system for assessment of HCV infection [17].  
Many health care facilities in Myanmar do not have the 
resources to implement routine HCV testing of blood 
donors given the current availability and the cost of 
the test.  The factors identiﬁed by the present study 
as associated with HCV infection could help local 
health personnel in the deferral of blood donors who 
are likely to be seropositive to HCV infection.
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